• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

WHO 2030 NTDs Roadmap: how science and partnerships can support the fight to end neglected diseases

Home > Viewpoints

WHO 2030 NTDs Roadmap: how science and partnerships can support the fight to end neglected diseases

Laboratory staff working
28 Jan 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
Nathalie Strub-Wourgaft

On 28 January 2021 the World Health Organization (WHO) launched its new 2030 Roadmap, which sets the direction in the response against neglected tropical diseases (NTDs) for the next decade.

Dr Nathalie Strub-Wourgaft, DNDi’s director of NTDs, explains what must be done to make the Roadmap a success.

What progress has been made since the launch of the previous WHO NTD Roadmap in 2011?

A number of achievements – one of which is particularly close to my heart. We’ve achieved the elimination of African sleeping sickness as a public health problem thanks to the development of new technologies, public commitment, and funding. We are down to less than 1,000 cases a year. This is a success we should really celebrate, even though more remains to be done!

Several countries have also eliminated at least one NTD as a public health problem.

New actors have become engaged in NTDs. On the funding side, there are new financing mechanisms such as the Global Health Innovative Technology Fund in Japan, and the European and Developing Countries Clinical Trials Partnership, which expanded its mandate to include NTDs. And at DNDi, we have built new collaborations for R&D, which allowed our pipeline of brand-new molecules and potential new drug candidates to grow significantly – notably for leishmaniasis, for example.

But this is not enough. We have not reached many of the objectives set in the first Roadmap, including objectives related to innovation.

What are the most critical gaps in innovation that must be addressed to achieve the goals of the new NTD Roadmap?

We still need better, safer, and affordable treatments for many NTDs: river blindness, Chagas disease, visceral leishmaniasis, cutaneous leishmaniasis, mycetoma, and sleeping sickness to name just the ones in DNDi’s portfolio.

It is important to note this isn’t just about treatments: before treating, we need to know where the patients are. We need continuing innovation on the diagnostics front, especially for tests that can be deployed at the primary healthcare level. The WHO Roadmap identifies diagnostics as a crucial area for R&D.

Another concern that gets too little attention are the needs of young women who do not have access to contraception and who need NTD treatments. They cannot be overlooked. At DNDi, with our partners, we have suggested a new approach to include women who are pregnant or susceptible of becoming pregnant in clinical trials.

And the NTD R&D landscape is obviously critical. In order to achieve all these ambitious objectives, sustained funding and increased engagement from countries is essential.

The new Roadmap calls for better integration of NTD care within national health systems. Why is that so important?

Integration means moving resources for healthcare delivery from siloed, disease-specific approaches to more holistic horizontal ones. That means that health workers who are trained in testing for sleeping sickness, for example, are also looking for other diseases that are prevalent in their region.

This is critical because it enables a patient-centric response. Someone presenting with an NTD should also be treated for associated disorders. This is why the WHO Roadmap highlights the need to address cross-cutting issues, such as water, sanitation, and hygiene, mental health, nutrition, and non-communicable diseases. In our clinical trials, we are often surprised to see that NTD patients also suffer from other undiagnosed disorders. The neglect does not stop at NTDs.

An additional priority is ensuring access. It’s quite clear that just because you have developed a drug it doesn’t magically reach patients. Mechanisms to support access are needed to integrate treatments into health systems, ensuring health workers and patients alike are aware that new treatments are available and know how they should be used. At DNDi, the approach is to consider access as an essential component within R&D efforts, by developing tools that can be delivered as easily as possible, as close as possible to patients’ homes. That is why we focus on affordability, and on all-oral treatments.

When we talk about health systems integration, we need to further investigate the social and anthropological dimensions of treating patients. Patient trust and acceptability are vital. Some NTDs are extremely stigmatizing and can be surrounded by a lot of misinformation and suspicion. This can also affect the mental health of people with NTDs.

Community groups – such as those used successfully for HIV – need to be actively involved and supported to represent patient needs and build trust within the community. Traditional practitioners should be part of these programmes where they play an important role in the community. The changes brought by innovation need to be accepted at all the levels of the healthcare delivery chain.

Doctor with patient

What role do you see partnerships playing in the fight against NTDs?

DNDi is a living example of the power of partnerships, where partners share common goals and have a pragmatic, flexible, and adaptive way of working together.

We saw this in the development and registration of fexinidazole for sleeping sickness. This revolutionary treatment was made possible because of partnerships – multi-dimensional ones – involving the National Sleeping Sickness Control Program in the Democratic Republic of Congo, the WHO, our industrial partner Sanofi, public and private donors such as the Bill & Melinda Gates Foundation, academia, research institutions such as the Swiss Tropical and Public Health Institute, and Médecins Sans Frontières (MSF).

The role of endemic country researchers and clinicians shouldn’t be underestimated. It’s the HAT Platform of sleeping sickness researchers and clinicians, coordinated by DNDi, that started by defining the target product profile – the ideal characteristics of a drug we hope to develop. It then continued with the clinical research and now with work to scale up access to fexinidazole. In the future, this platform could evolve to tackle other NTDs.

How has the COVID-19 pandemic impacted the response to NTDs? 

What the COVID-19 crisis has shown is that when there is global mobilization, commitment from all actors, and a sense of crisis, medical research can move incredibly fast.

It’s also showing that a mix of short, medium, and long-term approaches for R&D is needed. This is the same strategy that we have followed for NTDs, by focusing both on repurposed drugs but also on discovering and developing new chemical entities.

Those are the positives. As for the negatives, aside from the immediate disruption, the loss of life, and the unprecedented pressure on healthcare workers: the attention of researchers, and the resources of countries have shifted. This is very concerning. This will definitely impact our chances of having enough human and financial resources to address NTDs.

What message would you send to a global health community overwhelmed by COVID-19 to keep its attention on NTDs as the 2030 Roadmap is launched?

NTDs kill, disfigure, stigmatize, or debilitate millions of people every year – often the poorest of the poor. They bring financial devastation to affected families, feeding a vicious circle of poverty. Out of the 1.7 billion people affected, almost half are children.

This last decade has demonstrated that investments in R&D can bring crucially important lifesaving tools, such as rapid diagnostic tests or new treatments, to neglected patients. It can be done. We have shown this isn’t a situation we should just accept, but one we should work together to change.

The global community must not forget NTDs, even with COVID-19 occupying all our efforts now. Climate change will certainly make things worse, as some climate-sensitive NTDs will likely spread. We have a moral imperative to end the neglect of people affected by NTDs. We have to act collectively. And we have to act now.

Photo credit: Ana Ferreira-DNDi, Neil Brandvold-DNDi

Climate change Funding Gender Partnership Registration & access Strengthening Capacities COVID-19 Chagas disease Cutaneous leishmaniasis Filaria: river blindness Mycetoma Sleeping sickness Visceral leishmaniasis

Read, watch, share

Loading...
Doctor with patient in hospital setting
News
15 Aug 2022

DNDi Media Workshop 2022 for Asian Science and Health Journalists

Viewpoints
12 Aug 2022

The climate crisis and infectious diseases: what role for DNDi?

Laboratory assistant conducts analysis at laboratory in Peru
Press releases
3 Aug 2022

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

From neglect to hope: Voices of leishmaniasis film poster
Videos
2 Aug 2022

From neglect to hope: Voices of leishmaniasis

Mother with her two children, Indian woman, and African doctor
Publications
1 Aug 2022

New hope for leishmaniasis

Lab activities
Press releases
27 Jul 2022

Korean cutting-edge technology to reduce the cost of promising drug for neglected disease visceral leishmaniasis

Statements
18 Jul 2022

DNDi‘s comments on the working draft of the WHO CAll for the consideration of the INB at its second meeting

Man standing by the river
Publications
15 Jul 2022

DNDi 2021 Annual Report

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesNo description
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
_hjSessionUser_11288441 yearNo description
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo